# A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

> **NCT01849874** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 341 (actual)

## Conditions studied

- Low-grade Serous Ovarian Cancer
- Low-grade Serous Fallopian Tube Cancer
- Low-grade Serous Peritoneal Cancer

## Interventions

- **DRUG:** MEK162, MEK inhibitor; oral
- **DRUG:** Physician's choice chemotherapy

## Key facts

- **NCT ID:** NCT01849874
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-06-27
- **Primary completion:** 2016-01-20
- **Final completion:** 2022-08-23
- **Target enrollment:** 341 (ACTUAL)
- **Why stopped:** Per recommendation of the DMC, enrollment into the study was discontinued in April 2016 after the planned interim efficacy analysis showed the hazard ratio for PFS crossed the predefined futility boundary.
- **Last updated:** 2023-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01849874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01849874, "A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01849874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*